BioCentury
ARTICLE | Clinical News

Glembatumumab vedotin: Phase II started

December 22, 2014 8:00 AM UTC

Celldex began an open-label, U.S. Phase II trial to evaluate IV glembatumumab vedotin on day 1 of each 21-day cycle in about 60 patients who have received =4 prior lines of anticancer regimens, includ...